Please login to the form below

Not currently logged in
Email:
Password:

Keytruda shows significant and meaningfully improvement in kidney cancer

Merck announces results from its phase 3 KEYNOTE-564 trial

Merck and Co

Merck, known as MSD outside the United States and Canada, yesterday announced results from its pivotal phase 3 KEYNOTE-564 trial evaluating Keytruda, its anti-PD-1 therapy.

The trial met its primary endpoint of disease-free survival (DFS) for the potential adjuvant treatment of patients with renal cell carcinoma (RCC) following the surgical removal of a kidney or following nephrectomy and resection of metastatic lesions.

The interim analysis was conducted by an independent Data Monitoring Committee, and Keytruda showed significant and meaningfully improvement compared with placebo in DFS.

Merck’s press release stated: ‘The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies.’

The press release added that results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories said: “Since its first approval in renal cell carcinoma nearly two years ago, Keytruda has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma.

“This new data is the result of our research to evaluate the role of Keytruda in helping patients with earlier stages of disease and are the first positive results for an anti-PD-1 therapy in the adjuvant treatment of patients with renal cell carcinoma. We look forward to sharing results of KEYNOTE-564 with the medical community and regulatory authorities as soon as possible.”

Keytruda is currently approved in the US, Europe and Japan in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma.

Article by
Iona Everson

9th April 2021

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....